Financings in Brief: Meridian Diagnostics
This article was originally published in The Gray Sheet
Meridian Diagnostics: Immunodiagnostic kit manufacturer files registration statement with SEC for an offering of convertible subordinated debentures worth a principal amount of $12.5 mil. Net proceeds from the offering will be used for "possible acquisitions and licensing of products or technologies and general corporate purposes," Meridian says. Underwriters Roney & Co. will receive an over-allotment option to buy $1.9 mil. in convertible debentures...
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.